|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
This expert group recommends testing for KRAS and NRAS status in all patients with metastatic CRC being considered for anti-epidermal growth factor receptor (anti-EGFR) therapy, as this type of treatment should only be used in patients not harbouring mutations in these genes.
|
25373533 |
2015 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Characteristics and prognosis of CRC with NRAS mutations are different from those with KRAS or BRAF mutations.
|
24806883 |
2014 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Recent studies have demonstrated that, in advanced colorectal carcinoma (CRC) patients, extended RAS (in KRAS exons 2-4 and NRAS exons 2-4) and BRAF mutations are negative predictors for anti-EGFR treatment efficacy and negative prognostic factor, respectively.
|
25262986 |
2014 |
|
Colorectal Carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
In this retrospective study for quality assessment of a next-generation sequencing assay, we examined BRAF, KRAS, and NRAS genes within the mitogen-activated protein kinase (MAPK) pathway and the PIK3CA gene within the phosphatidylinositol 3-kinase (mTOR) pathway in 744 CRC specimens submitted to our clinical diagnostics laboratory.
|
30481508 |
2019 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The Japanese Society of Medical Oncology (JSMO) previously published 2 editions of the clinical guidelines: "Japanese guidelines for testing of KRAS gene mutation in colorectal cancer" in 2008 and "Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients" in 2014.
|
29873882 |
2018 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Genomic biomarkers for the management of colorectal carcinoma are both well-established (ie, KRAS, NRAS) and emerging (BRAF, PIK3CA, and others) in respect to therapy selection and clinical trial eligibility.
|
29027537 |
2018 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
We have used SW48 and LIM1215 human colon cancer cell lines, quadruple wild-type for KRAS, NRAS, BRAF and PI3KCA genes, and their HER2-amplified (LIM1215-HER2 and SW48-HER2) derived cells to perform in vitro and in vivo studies in order to identify novel therapeutic strategies in HER2 gene amplified human colorectal cancer.
|
31164152 |
2019 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Large prospective clinical trials have shown only colorectal cancer (CRC) with wild-type KRAS and NRAS responds to anti-Epidermal Growth Factor Receptor treatment.
|
29921458 |
2018 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Mutational status for KRAS, NRAS, and BRAF genes should be performed on all colorectal carcinoma (CRC) specimens in order to guide targeted therapy selection for metastatic disease.
|
31290252 |
2019 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Somatic mutations in KRAS, NRAS, and BRAF genes are related to resistance to anti-EGFR antibodies in colorectal cancer.
|
25954997 |
2015 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
These tumors are less likely to have microsatellite instability than CRC with a V600E BRAF mutation and often harbor a KRAS or NRAS mutation.
|
31185985 |
2019 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Evaluation of the Idylla KRAS and NRAS mutation test in colorectal cancer tissue.
|
31207216 |
2019 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Cetuximab plus chemotherapy is a first-line treatment option in metastatic KRAS and NRAS wild-type colorectal cancer (CRC) patients.
|
27002107 |
2016 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Treatment of colorectal cancer (CRC) with monoclonal antibodies against epidermal growth factor receptor requires the assessment of the mutational status of exons 2, 3, and 4 of the NRAS and KRAS oncogenes.
|
29959022 |
2018 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
The added predictive value of additional biomarkers in the RAS-RAF-MAPK and PI3K-AKT-mTOR pathways in colorectal cancer is uncertain, which led us to systematically review the impact of alterations in KRAS (outside of exon 2), NRAS, BRAF, PIK3CA and PTEN in relation to the clinical benefit from anti-EGFR treatment.
|
24666267 |
2014 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
For comparative analyses of ras protein levels, we have probed Western blots of extracts from 9 normal human tissues and 55 pairs of colorectal carcinoma and matched control mucosa, using monoclonal antibodies (MAbs) specific for H-, K- or N-ras proteins.
|
9180144 |
1997 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Testing for NRAS mutation at codon Q61 is of therapeutic, prognostic, and diagnostic importance for metastatic melanoma, thyroid carcinoma, and colorectal carcinoma.
|
26712868 |
2016 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
In colorectal cancer, KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) mutations are associated with resistance to antiepidermal growth factor receptor monoclonal antibodies, and BRAF mutation is a molecular marker of poor prognosis.
|
29052598 |
2018 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We found "rare mutations" in RAS genes in nearly 14% of CRCs-i.e., in almost a quarter (24.0%) of KRAS exon 2 wild type CRCs, including 2.3% in KRAS exon 3, 8.2% in KRAS exon 4 and 3.4% in NRAS.
|
29666387 |
2018 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
- To evaluate the significance of NRAS Q61R mutant-specific immunohistochemistry in a cohort of colorectal carcinomas.
|
28353383 |
2017 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Four of the polymorphisms exhibited an increased colorectal cancer risk [GSTT1, NAT2 (phenotype), HRAS1, and ALDH2].
|
12433710 |
2002 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Five nonsynonymous germline variants on 4 cancer susceptible genes, CDH1, APC, MLH1, and NRAS, were observed in 6 patients with CRC (12%).
|
27121310 |
2016 |
|
Colorectal Carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Mutations of KRAS, NRAS, BRAF, and phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and deregulation of PTEN expression influence the responsiveness against anti-EGFR therapy in colorectal carcinomas.
|
23158210 |
2013 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Colorectal carcinomas (CRCs) are sensitive to treatment by anti-epidermal growth factor receptor (EGFR) antibodies only if they do not carry activating mutations in down-stream EGFR targets (KRAS/NRAS/BRAF).
|
29470838 |
2018 |
|
Colorectal Carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Indeed, activating mutations in the genes KRAS, NRAS and BRAF are the only predictive biomarkers for anti-EGFR antibody therapy routinely tested the clinic for advanced stages of CRC.
|
29788743 |
2018 |